Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.
This report is a detailed and comprehensive analysis for global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
GLP-1 agonists are a class of pharmaceutical agents used to treat both type 2 diabetes mellitus and obesity,including semaglutide,liraglutide,tirzepatide,and others,which can stimulate GLP-1 receptors,leading to increased insulin secretion in response to meals,decreased glucagon release,and slowed gastric emptying.While GLP-1 agonists can also promote weight loss by enhancing feelings of fullness and decreasing appetite.
This report is a detailed and comprehensive analysis for global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
- Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts, in consumption value ($ Million), 2021-2032
- Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
- Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
- Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for GLP-1 Agonists for the Treatment of both Diabetes and Obesity
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
- This report profiles key players in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, etc.
- This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
GLP-1 Agonists for the Treatment of both Diabetes and Obesity market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.Market segment by Type
- Semaglutide
- Liraglutide
- Tirzepatide
Market segment by Application
- Hospital and Clinic
- Retail Pharmacies
- Other
Market segment by players, this report covers
- Novo Nordisk
- Eli Lilly
Market segment by regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
- Chapter 1, to describe GLP-1 Agonists for the Treatment of both Diabetes and Obesity product scope, market overview, market estimation caveats and base year.
- Chapter 2, to profile the top players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity, with revenue, gross margin, and global market share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity from 2021 to 2026.
- Chapter 3, the GLP-1 Agonists for the Treatment of both Diabetes and Obesity competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
- Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
- Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and GLP-1 Agonists for the Treatment of both Diabetes and Obesity market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
- Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
- Chapter 12, the key raw materials and key suppliers, and industry chain of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
- Chapter 13, to describe GLP-1 Agonists for the Treatment of both Diabetes and Obesity research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Type
1.3.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type in 2025
1.3.3 Semaglutide
1.3.4 Liraglutide
1.3.5 Tirzepatide
1.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
1.4.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital and Clinic
1.4.3 Retail Pharmacies
1.4.4 Other
1.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size & Forecast
1.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast by Region
1.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region, (2021-2032)
1.6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.6 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
2.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novo Nordisk Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
2.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Eli Lilly Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Revenue
3.2.2 Top 3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
3.2.3 Top 6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Overall Company Footprint Analysis
3.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Region Footprint
3.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Type Footprint
3.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value and Market Share by Type (2021-2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2026)
5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2032)
6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
6.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
6.3.2 United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
6.3.3 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
6.3.4 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
7.3.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
7.3.2 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.3 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.4 United Kingdom GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.5 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.6 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region
8.3.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2032)
8.3.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.3 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.4 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.5 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.7 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
9.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
9.3 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
9.3.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
9.3.2 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
9.3.3 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
10.3.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
10.3.2 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10.3.4 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
11.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
11.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Chain
12.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Upstream Analysis
12.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Midstream Analysis
12.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Type
1.3.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type in 2025
1.3.3 Semaglutide
1.3.4 Liraglutide
1.3.5 Tirzepatide
1.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
1.4.1 Overview: Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital and Clinic
1.4.3 Retail Pharmacies
1.4.4 Other
1.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size & Forecast
1.6 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast by Region
1.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region, (2021-2032)
1.6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.6 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
2.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novo Nordisk Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
2.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Eli Lilly Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Revenue
3.2.2 Top 3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
3.2.3 Top 6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Overall Company Footprint Analysis
3.3.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Region Footprint
3.3.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Type Footprint
3.3.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value and Market Share by Type (2021-2026)
4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2026)
5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
6.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2032)
6.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
6.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
6.3.2 United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
6.3.3 Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
6.3.4 Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
7.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
7.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
7.3.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
7.3.2 Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.3 France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.4 United Kingdom GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.5 Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
7.3.6 Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
8.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
8.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region
8.3.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2032)
8.3.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.3 Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.4 South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.5 India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
8.3.7 Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
9.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
9.3 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
9.3.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
9.3.2 Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
9.3.3 Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2032)
10.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2032)
10.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
10.3.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2032)
10.3.2 Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
10.3.4 UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
11.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
11.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Chain
12.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Upstream Analysis
12.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Midstream Analysis
12.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 6. Novo Nordisk Major Business
Table 7. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
Table 8. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Novo Nordisk Recent Developments and Future Plans
Table 10. Eli Lilly Company Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
Table 13. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Eli Lilly Recent Developments and Future Plans
Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million) by Players (2021-2026)
Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Players (2021-2026)
Table 17. Breakdown of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3)
Table 18. Market Position of Players in GLP-1 Agonists for the Treatment of both Diabetes and Obesity, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 19. Head Office of Key GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players
Table 20. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Type Footprint
Table 21. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Application Footprint
Table 22. GLP-1 Agonists for the Treatment of both Diabetes and Obesity New Market Entrants and Barriers to Market Entry
Table 23. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Mergers, Acquisition, Agreements, and Collaborations
Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (USD Million) by Type (2021-2026)
Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Type (2021-2026)
Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Forecast by Type (2027-2032)
Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026)
Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Forecast by Application (2027-2032)
Table 29. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 30. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 31. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 40. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 41. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 42. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 43. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 44. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 45. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2026) & (USD Million)
Table 46. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2027-2032) & (USD Million)
Table 47. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 48. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 49. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 50. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 51. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 52. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 53. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 54. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 55. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 56. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 57. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 58. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 59. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Upstream (Raw Materials)
Table 60. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Typical Customers
Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 6. Novo Nordisk Major Business
Table 7. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
Table 8. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Novo Nordisk Recent Developments and Future Plans
Table 10. Eli Lilly Company Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product and Solutions
Table 13. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Eli Lilly Recent Developments and Future Plans
Table 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (USD Million) by Players (2021-2026)
Table 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Players (2021-2026)
Table 17. Breakdown of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3)
Table 18. Market Position of Players in GLP-1 Agonists for the Treatment of both Diabetes and Obesity, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 19. Head Office of Key GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players
Table 20. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Type Footprint
Table 21. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market: Company Product Application Footprint
Table 22. GLP-1 Agonists for the Treatment of both Diabetes and Obesity New Market Entrants and Barriers to Market Entry
Table 23. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Mergers, Acquisition, Agreements, and Collaborations
Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (USD Million) by Type (2021-2026)
Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Type (2021-2026)
Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Forecast by Type (2027-2032)
Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026)
Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Forecast by Application (2027-2032)
Table 29. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 30. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 31. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 35. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 36. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 37. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 40. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 41. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 42. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 43. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 44. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 45. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2021-2026) & (USD Million)
Table 46. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Region (2027-2032) & (USD Million)
Table 47. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 48. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 49. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 50. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 51. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 52. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 53. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2021-2026) & (USD Million)
Table 54. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type (2027-2032) & (USD Million)
Table 55. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2021-2026) & (USD Million)
Table 56. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application (2027-2032) & (USD Million)
Table 57. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2021-2026) & (USD Million)
Table 58. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Country (2027-2032) & (USD Million)
Table 59. Global Key Players of GLP-1 Agonists for the Treatment of both Diabetes and Obesity Upstream (Raw Materials)
Table 60. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Typical Customers
LIST OF FIGURES
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture
Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type in 2025
Figure 4. Semaglutide
Figure 5. Liraglutide
Figure 6. Tirzepatide
Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application in 2025
Figure 9. Hospital and Clinic Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Other Picture
Figure 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region (2021-2032)
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region in 2025
Figure 17. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 20. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Players in 2025
Figure 24. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Player Revenue in 2025
Figure 26. Top 3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
Figure 27. Top 6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
Figure 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Type (2021-2026)
Figure 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share Forecast by Type (2027-2032)
Figure 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Application (2021-2026)
Figure 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share Forecast by Application (2027-2032)
Figure 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 35. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 42. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region (2021-2032)
Figure 49. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 52. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 55. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 56. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 57. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 66. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
Figure 67. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
Figure 68. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Picture
Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type in 2025
Figure 4. Semaglutide
Figure 5. Liraglutide
Figure 6. Tirzepatide
Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application in 2025
Figure 9. Hospital and Clinic Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Other Picture
Figure 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Market GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 15. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region (2021-2032)
Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region in 2025
Figure 17. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 18. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 19. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 20. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 21. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Share by Players in 2025
Figure 24. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 25. Market Share of GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Player Revenue in 2025
Figure 26. Top 3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
Figure 27. Top 6 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share in 2025
Figure 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Type (2021-2026)
Figure 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share Forecast by Type (2027-2032)
Figure 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Share by Application (2021-2026)
Figure 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share Forecast by Application (2027-2032)
Figure 32. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 33. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 34. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 35. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 36. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 37. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 39. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 40. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 41. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 42. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 43. United Kingdom GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 44. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 45. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 46. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 47. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 48. Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Region (2021-2032)
Figure 49. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 50. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 51. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 52. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 53. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 54. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 55. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 56. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 57. South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 58. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 59. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 60. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Type (2021-2032)
Figure 61. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Application (2021-2032)
Figure 62. Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value Market Share by Country (2021-2032)
Figure 63. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 64. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 65. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Consumption Value (2021-2032) & (USD Million)
Figure 66. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Drivers
Figure 67. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Restraints
Figure 68. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
